Themed collection organ-on-a-chip systems: translating concept into practice

Thought leader Michael Shuler provides an update on the Lab on a Chip thematic collection organ-on-a-chip systems: translating concept into practice.

Standards can demonstrate technological and biological relevance, increase industry implementation and support regulatory acceptance. This article will give you an overview on the state of play and future needs in standardisation for OoC.

Opportunities in the drug discovery/development process for potential MPS incorporation.

The integrative responses of the cardiovascular (CV) system are essential for maintaining blood flow to provide oxygenation, nutrients, and waste removal for the entire body.

In this review, we describe some of the advances made for tissue-specific microphysiological systems and outline the advantages and challenges of applying and further developing MPS technology in preclinical biopharmaceutical research.

Potential applications of MPS in the ADME discipline.

Selected skin MPS features desired to advance further adoption within the pharmaceutical industry.

Drug developers seek specific advancements in the development and qualification of microphysiological lung models for the evaluation of drug safety; here these essential elements are discussed from the perspective of the biopharmaceutical industry.

Drug-induced gastrointestinal toxicities (DI-GITs) are among the most common adverse events in clinical trials.

The human kidney contains approximately one million nephrons.

This pharmaceutical industry guidance based on a 3-staged benchmarking strategy aims to help MPS developers and end users identify what could be the most valuable models for safety risk assessment, as well as provide an overview of contexts of use.

Microphysiological systems (MPS) are complex and more physiologically realistic cellular in vitro tools that aim to provide more relevant human in vitro data for quantitative prediction of clinical pharmacokinetics while also reducing the need for animal testing.

VMTs recapitulate in vivo drug responses and also reconstitute the cellular diversity of tumors.

Our microfluidic model of early metastatic niche reproduced the extravasation of breast cancer cells in presence of immune blood cells and allowed us to test the effect of an already approved inhibitor of integrin β₃ on cancer cell extravasation.

Identification and testing of personalized anti-angiogenic treatments for clear cell renal cell carcinoma using patient-derived microfluidic models of normal and tumor-associated blood vessels.

In a novel, integrated platform, integration of human bone tumor and cardiac tissues improved predictive accuracy of linsitinib efficacy and safety. This platform mimicked clinical trial results, unlike other pre-clinical models.

The developed multiplexed chip contains 8 channels that can be accessed individually or simultaneously with increased throughput. The visual inspection of cells in the device was improved with our fabricated 2 μm-thick porous PDMS membrane.

HepaChip-MP: a 24-culture-chamber, automated microfluidic in vitro model of the liver sinusoid in multiwellplate format.

An integrated biomimetic array chip (iBAC) enables co-culture of three-dimensional (3D) liver and tumor microtissues for anticancer bioactivity screening at throughputs.

Lymphatic organotypic in vitro model allows the examination of components of the tumor microenvironment (e.g., ECM density, cancer cells) in lymphatic vessel biology in the context of cancer, providing insights into potential therapeutic targets.

The Microphysiology Systems Database (MPS) is a critical tool for the design, management, analysis, and sharing of MPS study data.

We demonstrate that the integration of complex human synovial organ cultures in a lab-on-a-chip provides reproducible and reliable information on how systemic stress factors affect synovial tissue architectures using light scatter biosensing.

High costs are a key challenge in “democratization” of organ-chip research. We present a low-resource barrier-on-chip based on tape, and use it to model small intestine and its response to chili peppers (capsaicinoids).

Body-on-a-chip in vitro systems are a promising technology that aims to increase the predictive power of drug efficacy and toxicity in humans when compared to traditional animal models.

We have constructed a mechanism-based pharmacokinetic model for triazolam and its metabolites in the entero-hepatic two-organ MPS, and extrapolated the kinetic information obtained with the MPS to the plasma concentration profiles in humans.

A 3D cell culture system that mimics the lung cancer microenvironment was used to investigate the effect of exosomes encapsulating miR-497 on tumor growth and angiogenesis, and could be a predictive, cost-efficient translational tool to develop targeted cancer therapy.

Organ-on-chips made of blood: personalized medicine with microfluidics.

Modular multi-organ perfusion systems offer the unique opportunity to customize different physiological systemic interactions.

An electrochemical permeability assay that enables the on-chip measurement of endothelial permeability with significant advantages over traditional fluorescent tracer-based assays.